These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 34681879)
1. Identification of Tumor Antigens in Ovarian Cancers Using Local and Circulating Tumor-Specific Antibodies. Da Gama Duarte J; Quigley LT; Young AR; Hayashi M; Miyazawa M; Lopata A; Mancuso N; Mikami M; Behren A; Meeusen E Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681879 [TBL] [Abstract][Full Text] [Related]
2. Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer. Schock H; Surcel HM; Zeleniuch-Jacquotte A; Grankvist K; Lakso HÅ; Fortner RT; Kaaks R; Pukkala E; Lehtinen M; Toniolo P; Lundin E Endocr Relat Cancer; 2014; 21(6):831-44. PubMed ID: 25270324 [TBL] [Abstract][Full Text] [Related]
3. Autoantibody biomarkers for the detection of serous ovarian cancer. Katchman BA; Chowell D; Wallstrom G; Vitonis AF; LaBaer J; Cramer DW; Anderson KS Gynecol Oncol; 2017 Jul; 146(1):129-136. PubMed ID: 28427776 [TBL] [Abstract][Full Text] [Related]
4. Elevated serum 8-OHdG is associated with poor prognosis in epithelial ovarian cancer. Pylväs M; Puistola U; Laatio L; Kauppila S; Karihtala P Anticancer Res; 2011 Apr; 31(4):1411-5. PubMed ID: 21508394 [TBL] [Abstract][Full Text] [Related]
5. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390 [TBL] [Abstract][Full Text] [Related]
6. Detection of phosphatidylserine-positive exosomes as a diagnostic marker for ovarian malignancies: a proof of concept study. Lea J; Sharma R; Yang F; Zhu H; Ward ES; Schroit AJ Oncotarget; 2017 Feb; 8(9):14395-14407. PubMed ID: 28122335 [TBL] [Abstract][Full Text] [Related]
7. LyGDI is a promising biomarker for ovarian cancer. Zhen H; Yang S; Wu H; Wang S; Lv J; Ma L; Zhang X Int J Gynecol Cancer; 2010 Apr; 20(3):316-22. PubMed ID: 20375790 [TBL] [Abstract][Full Text] [Related]
8. Circulating prolactin levels and risk of epithelial ovarian cancer. Clendenen TV; Arslan AA; Lokshin AE; Liu M; Lundin E; Koenig KL; Berrino F; Hallmans G; Idahl A; Krogh V; Lukanova A; Marrangoni A; Muti P; Nolen BM; Ohlson N; Shore RE; Sieri S; Zeleniuch-Jacquotte A Cancer Causes Control; 2013 Apr; 24(4):741-8. PubMed ID: 23378139 [TBL] [Abstract][Full Text] [Related]
9. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Asher V; Lee J; Innamaa A; Bali A Clin Transl Oncol; 2011 Jul; 13(7):499-503. PubMed ID: 21775277 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses. Dewan R; Dewan A; Jindal M; Bhardawaj M Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480 [TBL] [Abstract][Full Text] [Related]
11. The risk of malignancy index (RMI) in diagnosis of ovarian malignancy. Moolthiya W; Yuenyao P Asian Pac J Cancer Prev; 2009; 10(5):865-8. PubMed ID: 20162854 [TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer. Mury D; Woelber L; Jung S; Eulenburg C; Choschzick M; Witzel I; Schwarz J; Jaenicke F; Mahner S J Cancer Res Clin Oncol; 2011 Jul; 137(7):1131-7. PubMed ID: 21344262 [TBL] [Abstract][Full Text] [Related]
13. Detection of serum autoantibodies to tumor suppressor gene p53 with a new enzyme-linked immunosorbent assay in patients with ovarian cancer. Marx D; Frey M; Zentgraf H; Adelssen G; Schauer A; Kuhn W; Meden H Cancer Detect Prev; 2001; 25(2):117-22. PubMed ID: 11341346 [TBL] [Abstract][Full Text] [Related]
14. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Budiu RA; Mantia-Smaldone G; Elishaev E; Chu T; Thaller J; McCabe K; Lenzner D; Edwards RP; Vlad AM Cancer Immunol Immunother; 2011 Jul; 60(7):975-84. PubMed ID: 21461842 [TBL] [Abstract][Full Text] [Related]
15. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma. S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147 [TBL] [Abstract][Full Text] [Related]
16. Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer. Ma Y; Wang X; Qiu C; Qin J; Wang K; Sun G; Jiang D; Li J; Wang L; Shi J; Wang P; Ye H; Dai L; Jiang BH; Zhang J Cancer Sci; 2021 Feb; 112(2):537-549. PubMed ID: 33185955 [TBL] [Abstract][Full Text] [Related]
17. Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer. Tang L; Yang J; Ng SK; Rodriguez N; Choi PW; Vitonis A; Wang K; McLachlan GJ; Caiazzo RJ; Liu BC; Welch WR; Cramer DW; Berkowitz RS; Ng SW Eur J Cancer; 2010 Jan; 46(1):170-9. PubMed ID: 19926475 [TBL] [Abstract][Full Text] [Related]
18. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer]. Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310 [No Abstract] [Full Text] [Related]